Listed

Gentherm Inc: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 1, 2019 and accepted by EDGAR at May 1, 2019, 16:17 ET.

Share

Management's discussion and analysis

As filed, 22,762 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward-Looking Statements

This Report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as our ability to execute our new strategic plan, our ability to finance sufficient working capital, the amount of availability under our credit agreement and other indebtedness, our ability to continue to maintain or increase sales and profits of our operations, and the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 1 to the consolidated condensed financial statements. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified and are based on management’s current expectations and beliefs. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent reports filed with or furnished to the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated financial statements and related notes thereto included elsewhere in this Report and in our Annual Report on Form 10-K for the year ended December 31, 2018.

Overview

Gentherm Incorporated is a global technology and industry leader in the design, development, and manufacturing of innovative thermal management technologies. Our products provide solutions for automotive passenger climate comfort and convenience, battery thermal management and cell connecting systems, as well as patient temperature management within the health care industry. Our automotive products can be found on the vehicles of nearly all major automotive manufacturers operating in North America, Europe and Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities and to identify future thermal technology product opportunities in both automotive and other markets. We concentrate our research on the development of new technologies and new applications from existing technologies to create product and market opportunities for a wide array of thermal management solutions.

Our automotive products are sold to automobile and light truck OEMs or their tier one suppliers. Inherent to the automotive supplier market are costs and commitments that are incurred well in advance of the receipt of orders and resulting revenues from customers. This is due in part to automotive manufacturers requiring the design, coordination and testing of proposed new components and sub-systems. Revenues from these expenditures are typically not realized for two to three years due to this development cycle.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Industrial. See Note 4 to the consolidated condensed financial statements for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income. The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

Sale of Cincinnati Sub-Zero Industrial Chamber Business (CSZ-IC)

On February 1, 2019, as part of the Company’s Fit-for-Growth initiative to eliminate investments in non-core businesses, we completed the sale of the Cincinnati Sub-Zero industrial chamber business (“CSZ-IC”) and former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47.5 million, including $2.5 million of the cash proceeds were placed into an escrow account for a period of up to one year as partial security for the Company’s obligations under the sale agreement. In connection with the sale, Gentherm entered into an operating lease agreement for a portion of the office and manufacturing building space purchased by Weiss Technik North America, Inc. The Company recognized a $5.0 million pre-tax gain on the sale of CSZ-IC during the three-month period ended March 31, 2019.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting Policies and Basis of Presentation,” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. With the exception of leases, there have been no significant accounting policy changes during the three-month period ended March 31, 2019. See Note 10 for information about the adoption of ASU 2016-02, “Leases”.

Results of Operations First Quarter 2019 Compared with First Quarter 2018

Product revenues. Product revenues by product category, in thousands, for the three-month period ended March 31, 2019 (“First Quarter 2019) and 2018 (“First Quarter 2018) are as follows:

Three Months Ended March 31, 2019 2018 % Change
Climate Control Seats (CCS) $94,354 $88,218 7.0%
Seat Heaters 73,920 84,220 (12.2)%
Steering Wheel Heaters 16,970 17,557 (3.3)%
Automotive Cables 23,749 26,865 (11.6)%
Battery Thermal Management (BTM)(a) 10,745 4,161 158.2%
Electronics 12,852 15,188 (15.4)%
Other Automotive 9,767 6,212 57.2%
Subtotal Automotive $242,357 $242,421 —%
Remote Power Generation (GPT) 3,959 4,662 (15.1)%
Industrial Chambers 3,418 10,213 (66.5)%
Gentherm Medical 8,187 7,290 12.3%
Subtotal Industrial $15,564 $22,165 (29.8)%
Total Company $257,921 $264,586 (2.5)%

a) Battery Thermal Management or BTM product revenues include Gentherm’s automotive grade, low cost, heat resistant fans and blowers used by customer for battery cooling through ventilation and production level shipments of the advanced TED based active cool system.

Product revenues during First Quarter 2019 were $257.9 million compared with product revenues of $264.6 million during First Quarter 2018, a decrease of $6.7 million, or 2.5%. Product revenues in the automotive segment decreased $64 thousand to $242.4 million during First Quarter 2019 as compared to First Quarter 2018. During First Quarter 2019, the relative market value of the Euro declined against the US Dollar, which had a negative impact on our product revenues from sales to customers in Europe, much of which are denominated in European Euros. Adjusting for the impact from foreign currency translation, First Quarter 2019 automotive product revenues would have been $249.1 million, or 2.8% higher than automotive revenues during First Quarter 2018. The growth in product revenues in the automotive segment was driven by higher sales of CCS and BTM, partially offset by lower sales of seat heaters, steering wheel heaters and automotive cables.

Our automotive segment revenues outperformed automotive vehicle product volumes during First Quarter 2019, despite a 6.7% decrease in actual light vehicle production in the Company’s key markets, including North America, Europe, Japan, Korea and China, as compared to light vehicle production during First Quarter 2018.

Product revenues in the industrial segment revenues decreased $6.6 million, or 29.8%, to $15.6 million during First Quarter 2019 due to the sale of CSZ-IC on February 1, 2019. Product revenues from GPT during First Quarter 2019 were $4.0 million compared to $4.7 million during First Quarter 2018, a decrease of $703 thousand, or 15.1%. These decreases were partially offset by higher production revenues at Gentherm Medical. Gentherm Medical product revenues increased $900 thousand, or 12.3%, to $8.2 million during First Quarter 2019. At March 31, 2019, GPT was classified as held for sale on Gentherm’s consolidated condensed balance sheet.

Cost of Sales. Cost of sales was $182.6 million during First Quarter 2019 compared to $183.3 million during First Quarter 2018, a decrease of $730 thousand, or 0.4%. Adjusting for the impact from foreign currency translation, cost of sales during First Quarter

2019 would have been $187.3 million, or 2.2% higher as compared to First Quarter 2018. This increase was due to the higher automotive product revenues, increased tariffs, higher labor costs and higher product costs on BTM associated with the launch phase of the new actively cooled technology programs. These items were partially offset by savings realized from Fit-for-Growth cost reduction initiatives.

Net Research and Development Expenses. Net research and development expenses were $18.9 million during First Quarter 2019 compared to $23.3 million during First Quarter 2018, a decrease of $4.4 million, or 18.9%. The decrease in net research and development expenses is a direct result of the Company’s focused portfolio and Fit-for-Growth cost reduction initiatives.

Research and development reimbursement totaled $3.7 million during First Quarter 2019 compared to $2.4 million during First Quarter 2018. This increase was mainly attributable to higher-than-normal development expense reimbursements paid by customers for products launched during the period.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $32.6 million during First Quarter 2019, a decrease of $3.8 million, or 10.5%, from $36.4 million during First Quarter 2018. The decrease was primarily driven by the impact of the Fit-for-Growth cost reduction initiatives and the sale of CSZ-IC on February 1, 2019.

Restructuring expenses. The Company recognized $1.9 million in restructuring expenses during First Quarter 2019 associated with the Fit-for-Growth program compared to $865 thousand recognized in First Quarter 2018, an increase of $1.1 million or 121.3%. These costs primarily related to the sale of CSZ-IC and the marketing of GPT to potential buyers.

Foreign currency gain (loss). During First Quarter 2019 we incurred a net foreign currency gain of $203 thousand which included a net realized loss of $791 thousand and a net unrealized gain of $994 thousand. The unrealized loss was primarily the result of holding significant amounts of U.S. Dollar cash at our subsidiaries in Europe which have the European Euro as the functional currency and due to certain intercompany relationships between these European subsidiaries and our U.S. based companies. During First Quarter 2018, we had a foreign currency loss of $4.6 million which included an unrealized loss of $3.6 million. In comparison to First Quarter 2018, the foreign currency impact during First Quarter 2019 was lower due to a smaller change in currency exchange rates during First Quarter 2019 as compared to First Quarter 2018.

Gain on sale of business. On February 1, 2019, as part of Company’s Fit-for-Growth initiative to eliminate investments in non-core businesses, we completed the sale of the CSZ-IC and former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47.5 million, including $2.5 million of cash proceeds placed into an escrow account for a period of up to one year. The Company recognized a pre-tax gain of $5.0 million on the sale of CSZ-IC during the three-month period ended March 31, 2019.

Impairment loss. During the First Quarter 2019, the Company recorded an impairment loss totaling $10.5 million associated with the Company’s plans to divest GPT. The loss is not expected to be deductible for income tax purposes.

Income Tax Expense. We recorded an income tax expense of $6.9 million during First Quarter 2019 on earnings before income tax of $15.3 million. The pre-tax earnings amount included the non-deductible impairment loss of $10.5 million. Adjusting for the impairment loss, the effective tax rate was 26.7% for the First Quarter 2019. During First Quarter 2018, we recorded an income tax expense of $3.0 million on earnings before tax of $16.0 million, or 19.0%. The effective tax rate for First Quarter 2018 differed from the Federal statutory rate of 21% primarily due to certain intercompany transactions which disproportionately benefited lower tax rate jurisdictions, partly offset by unfavorable effects from the U.S. tax reform, such as global intangible low-tax income (“GILTI”), enacted in December 2017. The effective tax rate for First Quarter 2019 was higher than the Federal statutory rate of 21% primarily due to the impact of higher statutory rates for our subsidiaries operating in foreign jurisdictions and effects from the U.S. tax reform, such as GILTI.

Liquidity and Capital Resources

Cash and Cash Flows

The Company has funded its financial needs primarily through cash flows from operating activities and equity and debt financings. Our new strategic plan sets forth a capital allocation strategy that includes a targeted debt-to-earnings leverage ratio and allows for some of our cash flows to be paid back to investors through Common Stock repurchases. On June 25, 2018, our Board of Directors increased the Company’s stock repurchase authorization to $300 million, of which $138.6 million of availability remained as of March 31, 2019. This authorization expires on December 16, 2020. Based on its current operating plan, management believes cash and cash equivalents at March 31, 2019, together with cash flows from operating activities, and borrowings available under our credit agreement, are sufficient to meet operating and capital expenditure needs, and to service debt, for at least the next 12 months.

However, if cash flows from operations decline, we may need to obtain alternative sources of capital and reduce or delay capital expenditures, acquisitions and investments, all of which could impede the implementation of our business strategy and adversely affect our results of operations and financial condition. In addition, it is likely that we will need to complete one or more equity or debt financings if we consummate any significant acquisition or several smaller acquisitions. There can be no assurance that such capital will be available at all or on reasonable terms, which could adversely affect our future operations and business strategy.

The following table represents our cash and cash equivalents and restricted cash:

(In thousands)

Three Months Ended March 31, 2019 Three Months Ended March 31, 2018
Cash, cash equivalents and restricted cash at beginning of period $39,620 $103,172
Cash provided by operating activities 6,881 5,590
Cash provided by (used in) investing activities 42,378 (8,393)
Cash used in financing activities (47,401) (35,400)
Foreign currency effect on cash and cash equivalents (209) 5,513
Cash, cash equivalents and restricted cash at end of period $41,269 $70,482

Cash Flows From Operating Activities

We manage our cash, cash equivalents and restricted cash in order to fund operating requirements and preserve liquidity to take advantage of future business opportunities. The following table compares the cash flows from operating activities during First Quarter 2019 and First Quarter 2018:

(In thousands)

Operating Activities: Three Months Ended March 31, 2019 2018 Change
Net income $8,414 $12,966 $(4,552)
Non-cash adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization 11,052 12,892 (1,840)
Deferred income taxes 1,749 (707) 2,456
Stock compensation 1,968 2,202 (234)
Defined benefit plan (income) expense (617) 298 (915)
Provision for doubtful accounts 229 41 188
Loss on sale of property and equipment 178 85 93
Operating lease expense 1,333 — 1,333
Impairment loss 10,484 — 10,484
Gain on sale of business (4,970) — (4,970)
Net income before changes in operating assets and liabilities 29,820 27,777 2,043
Changes in operating assets and liabilities:
Accounts receivable (8,293) (9,691) 1,398
Inventory (229) 1,903 (2,132)
Prepaid expenses and other assets (5,553) (4,881) (672)
Accounts payable (2,079) 1,290 (3,369)
Accrued liabilities (6,785) (10,808) 4,023
Net cash provided by operating activities $6,881 $5,590 $1,291

28

Cash provided by operating activities during First Quarter 2019 was $6.9 million, representing an increase of $1.3 million from cash provided in operating activities during First Quarter 2018, which was $5.6 million. The following table highlights significant differences between the operating cash flows for the three-month periods ending March 31, 2019 and 2018, respectively:

(In thousands)

Net cash provided by operating activities during First Quarter 2018 $5,590
Increase from higher net income before changes in operating assets and liabilities 2,043
Changes in working capital, net 6,337
Other changes in working capital, net. (7,089)
Net cash provided by operating activities during First Quarter 2019 $6,881

Net cash provided by operating activities before changes in operating assets and liabilities increased during First Quarter 2019 due to non-cash impairment losses of $10.5 million, partially offset by a $5.0 gain recognized on the sale of CSZ-IC. Additionally, working capital, net provided favorable cash flows related to accounts payable and accrued liabilities and unfavorable amounts related to accounts receivable, inventory, and prepaid expenses and other assets.

The following table illustrates changes in working capital during First Quarter 2019:

(In thousands)

Working capital at December 31, 2018 $267,679
Increase in cash, cash equivalents and restricted cash 1,878
Impairment loss on assets classified as held for sale (10,484)
Foreign currency effect on working capital (1,018)
Increase in accounts receivable 8,627
Decrease in tax receivables (2,415)
Increase in inventory 84
Increase in prepaid expenses and other assets 4,223
Decrease in accounts payable 1,694
Decrease in accrued liabilities 1,815
Decrease in working capital due to the sale of a business (42,530)
Increase in net current assets classified as held for sale 5,974
Working capital at March 31, 2019 $235,527

The following table highlights significant transactions that contributed to the increase in cash, cash equivalents and restricted cash during the three-month period ended March 31, 2019:

(in Thousands)

Net cash provided by operating activities $6,881
Purchases of property and equipment (5,150)
Repayments of Debt (49,627)
Borrowings from U.S. Revolving Note 10,428
Stock repurchases (8,040)
Proceeds from the sale of CSZ-IC 47,500
Other items (114)
Increase in cash $1,878

In addition to these transactions, working capital was impacted by increases in accounts receivable, inventory, and prepaid expenses and other assets, and decreases in accounts payable, accrued liabilities and tax receivables. The changes in current assets and liabilities reflect the classification of additional assets related to GPT (disposal group) as held for sale during First Quarter 2019. All assets and liabilities of the disposal group are classified as held for sale within current assets and current liabilities, respectively, on the Company’s consolidated balance sheet as of March 31, 2019. See Note 12 to our consolidated condensed financial statement for additional information about the assets and liabilities classified as held for sale.

Cash Flows From Investing Activities

Cash used in investing activities was $42.4 million during First Quarter 2019, reflecting cash proceeds of $47.5 million related to the sale of CSZ-IC, partially offset by purchases of property and equipment related to the expansion of production capacity, totaling $5.1 million.

Cash Flows From Financing Activities

Cash used in financing activities was $47.4 million during First Quarter 2019, reflecting payments of principal on the U.S. Revolving Note, the DEG China Loan and the DEG Vietnam Loan totaling $49.6 million in aggregate partially offset by additional borrowings on the U.S. Revolving Note totaling $10.4 million. As of March 31, 2019, the total availability under the U.S. Revolving Note was $261.1 million. Cash was also paid in First Quarter 2019 for cancellations of restricted stock awards totaling $376 thousand, and for the repurchase of Common Stock totaling $8.0 million.

Off-Balance Sheet Arrangements

We use letters of credit to guarantee our performance under specific construction contracts executed by our subsidiaries, GPT and Gentherm Medical. The expiration dates of the letter of credit contracts coincide with the expected completion date of the contract. Extensions are normally made if performance obligations continue beyond the expected completion date. At March 31, 2019, we had outstanding letters of credit of $11 thousand, a decrease from $455 thousand at December 31, 2018.

Market risk

As filed, 5,705 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our exposure to market risk for changes in interest rates relates primarily to our debt obligations and foreign currency contracts. We have in the past, and may in the future, place our investments in bank certificates of deposits, debt instruments of the U.S. government, and in high-quality corporate issuers.

We are exposed to market risk from changes in foreign currency exchange rates, short-term interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to our debt obligations under our Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the European Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which we hedge our exposure to foreign currency exchange risks is one year. We had foreign currency derivative contracts with a notional value of $24.1 million and $33.3 million outstanding at March 31, 2019 and December 31, 2018, respectively.

The maximum length of time over which we hedge our exposure to price fluctuations in material commodities is two years. No commodity swap contracts were outstanding at March 31, 2019 or at December 31, 2018.

We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive income (loss) in the consolidated condensed balance sheet. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive income (loss) is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. We record the ineffective portion of foreign currency hedging instruments, if any, to foreign currency gain (loss) in the consolidated condensed statements of income. Though we continuously monitor the hedging program, derivative positions and hedging strategies, foreign currency forward exchange agreements have not always been designated as hedging instruments for accounting purposes.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of March 31, 2019 is set forth in Note 6 to the consolidated condensed financial statements included herein.

Interest Rate Sensitivity

The table presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. The instruments actual cash flows are denominated in U.S. dollars ($USD) or European Euros (€EUR), as indicated in parentheses.

March 31, 2019

(In thousands except rate information)

Liabilities Long Term Debt: Expected Maturity Date 2019 2020 2021 2022 2023 Thereafter Total Fair Value
Fixed Rate (€EUR) $449 — — — — — $449 $450
Fixed Interest Rate 4.25% 4.25%
Variable Rate ($USD) — — 88,854 — $— — $88,854 $88,854
Average Interest Rate 4.00% 4.00%
Fixed Rate ($USD) $2,500 $2,500 $2,500 $2,500 $1,250 — $11,250 $11,325
Fixed Interest Rate 5.21% 5.21% 5.21% 5.21% 5.21% 5.21%

31

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

March 31, 2019

(In thousands except rate information)

Anticipated Transactions And Related Derivatives $U.S. functional currency Forward Exchange Agreements: (Receive MXN/Pay USD$) Expected Maturity or Transaction Date 2019 2020 2021 2022 2023 Thereafter Total Fair Value
Total Contract Amount $24,114 — — — — — $24,114 $857
Average Contract Rate 20.53 20.53

Controls and procedures

As filed, 1,991 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2019, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting that was disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2018, we began implementing a remediation plan to address the material weakness mentioned above. The material weakness will not be considered remediated, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of 2019.

(b) Changes in Internal Control over Financial Reporting

During the three-month period ended March 31, 2019, we implemented new lease accounting processes in conjunction with the adoption of ASU 2016-02, "Leases," on January 1, 2019. These implementations resulted in a material change in a component of our internal control over financial reporting.

Except with respect to the remediation efforts referenced above and the changes related to the adoption of ASU 2016-02, there were no changes in the Company’s internal control over financial reporting during the three-month period ended March 31, 2019, that have materially affected, or are reasonable likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 254 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There were no material changes in our risk factors previously disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018. You should carefully consider the risks and uncertainties described therein.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-01-01 to 2019-03-31$257.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-01-01 to 2019-03-31$182.6mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-01-01 to 2019-03-31$75.3mus-gaap:GrossProfit
Research and development3 months2019-01-01 to 2019-03-31$18.9mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-01-01 to 2019-03-31$32.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-01-01 to 2019-03-31$21.8mus-gaap:OperatingIncomeLoss
Income tax3 months2019-01-01 to 2019-03-31$6.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-01-01 to 2019-03-31$8.4mus-gaap:ProfitLoss
Diluted EPS3 months2019-01-01 to 2019-03-31$0.25us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-01-01 to 2019-03-31$0.25us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-01-01 to 2019-03-3133,733,335 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2019-01-01 to 2019-03-31$6.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-01-01 to 2019-03-31$5.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2019-01-01 to 2019-03-31$8.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-03-31$38.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$401.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$763.0mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$166.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$284.6mus-gaap:Liabilities
Long-term debtAt period end2019-03-31$97.6mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2019-03-31$2.9mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2019-03-31$478.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-19-014823. Last ingested by Listed: Oct 26, 2026, 17:44 ET. Listed shows no prices and gives no investment advice.